BC Innovations | Jul 11, 2018
Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
BC Week In Review | Feb 17, 2017
Clinical News

NC-6300: Ph I data

An open-label, Japanese Phase I trial in 19 patients with advanced or recurrent malignant solid tumors either refractory to standard therapy or for whom no other viable treatments options were available showed that 15-225 mg/m...
BC Week In Review | Oct 31, 2016
Company News

NanoCarrier, Kowa deal

NanoCarrier said it accepted a proposal from Kowa to terminate a 2011 deal granting Kowa exclusive, worldwide rights to NC-6300 ; all rights revert to NanoCarrier. The candidate has completed Phase I trials in Japan...
BC Week In Review | Jul 25, 2016
Clinical News

Biosimilar trastuzumab: Phase III data

Top-line data from a double-blind, international Phase III trial in 725 patients with HER2-positive early breast cancer showed that ABP 980 plus paclitaxel and surgery was non-inferior to Herceptin trastuzumab plus paclitaxel and surgery on...
BC Week In Review | Jun 13, 2016
Clinical News

IMAB362: Phase II data

Top-line data from the open-label, European Phase II FAST trial in 161 patients with CLND18.2-positive advanced or recurrent gastric or gastroesophageal junction cancer who have not received previous chemotherapy showed that a loading dose of...
BC Innovations | Oct 22, 2015
Distillery Techniques

Techniques: Conjugation of nanoparticles to a peptide from HIV tat protein (HIV tat) to enhance tumor uptake of chemotherapies

Drug delivery HIV tat topoisomerase II (TOP2) Ellence Pfizer Inc. HIV tat protein (HIV tat)...
BC Week In Review | Aug 18, 2014
Clinical News

IMAB362: Completed Phase II enrollment

Ganymed completed enrollment of 210 patients who have not received previous chemotherapy in the open-label, international Phase II FAST trial comparing IMAB362 every 3 weeks plus chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX) vs. EOX...
BC Innovations | Dec 12, 2013
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Ataxia telangienctasia mutated (ATM); DNA damage response Mouse studies suggest anthracyclines could be used to treat sepsis by activating...
BC Week In Review | Jun 24, 2013
Clinical News

EndoTAG-1: Final Phase II data

Final data from an investigator-initiated Phase II trial in 15 patients with non-metastatic HER2-negative breast cancer showed that once-weekly 22 mg/m 2 EndoTAG-1 plus 70 mg/m 2 paclitaxel as neoadjuvant therapy led to a reduction...
Items per page:
1 - 10 of 47